MSE
APLS

MUFG Securities EMEA’s Apellis Pharmaceuticals APLS Stock Holding History

MUFG Securities EMEA’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-298,000
Closed -$9.51M – 140
2024
Q4 		$9.51M Buy
+298,000
New +$8.96M 0.16% 92

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MUFG Securities EMEA's APLS Position: Q1 2025 in Review

MUFG Securities EMEA sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 298,000 shares — an estimated $9.51M sold.

MUFG Securities EMEA first reported a position in APLS in Q4 2024 and held it in 1 quarter. The position peaked at $9.51M in Q4 2024. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

  • MUFG Securities EMEA reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • MUFG Securities EMEA sold 298,000 Apellis Pharmaceuticals shares in Q1 2025, an estimated $9.51M.
  • MUFG Securities EMEA first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • MUFG Securities EMEA's Apellis Pharmaceuticals position peaked at $9.51M in Q4 2024.
  • 255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on MUFG Securities EMEA's 13F filing for Q1 2025, filed 12 May 2025.